ImmunOs Gets Cash Injection To Advance Potential First-In-Class Cancer Agent

Swiss Biotech Banks $74m

It has proved tricky of late for European biotechs to raise funds, but Switzerland's ImmunOs has gathered a group of top-tier US and European investors to help push lead asset IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, towards the clinic.

US dollars
The funds will go towards development of ImmunOs’s lead program, IOS-1002 through Phase II trials. • Source: Archive

As new treatments go under the spotlight at the American Society of Clinical Oncology meeting in Chicago, ImmunOs Therapeutics AG has concluded a healthy financing round to help advance its new class of biologics for cancer which it hopes will soon feature at the world's largest oncology conference.

The Swiss biotech has announced the closing of an oversubscribed series B financing round totalling $74m, led by new investors...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip